ConductScience.org, home

Comparison · NCT04615624-9fdbc16c

Furosemide vs Placebo: Number of Participants Who Required Additional Antihypertensive Agents in an Hour After Allocation

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Furosemide vs Placebo: Number of Participants Who Required Additional Antihypertensive Agents in an Hour After Allocation. Trial comparisons, record NCT04615624-9fdbc16c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04615624-9fdbc16c

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2730.1510.442wilson
Risk in group 20.2190.110.388wilson
Risk difference, group 1 minus group 20.054-0.1540.255newcombe hybrid score
Risk ratio, group 1 over group 21.250.5282.95log
Odds ratio, group 1 over group 21.340.434.17log
Number needed to treat, for one more participant with the outcome on Furosemide than on Placebo18.5from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Furosemide
When patient meets inclusion criteria and is randomized to treatment drug, she receives 40mg /4 milliliters (mL) IV furosemide in addition to usual antihypertensive.~Furosemide: Furosemide, a loop diuretic
933OG000
Group 2PlaceboWhen patient meets inclusion criteria and is randomized to placebo, she receives one dose of 4mL normal saline in addition to usual antihypertensive.~Placebo: Normal saline732OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Number of Participants Who Required Additional Antihypertensive Agents in an Hour After Allocation
Description
Were any additional antihypertensive agents in hour after allocation
Time frame
Assessed from 0 minutes to 1 hour post-dose, 1-hour post-dose reported
Population

Source ClinicalTrials.gov

Trial

Title
Furosemide vs. Placebo for Severe Antepartum Hypertension
NCT number
NCT04615624
Phases
PHASE3
Conditions
Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions
Furosemide, Placebo
Lead sponsor
Melanie Maykin, MD
Results first posted
2024-04-18

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04615624-9fdbc16c